News
Findings From Long-Term Analysis of the Effects of LYBALVI" (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
2+ hour, 50+ min ago (620+ words) " 56-Week Post Hoc Analysis Demonstrated Sustained Reduction in Hard-to-Treat Negative Symptoms " The analysis showed decreased negative symptoms over the first four weeks in a pooled analysis of treatment arms (LYBALVI, olanzapine and placebo) in ENLIGHTEN-1 with continued improvement over the…...
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
2+ week, 5+ hour ago (157+ words) The annual prevalence of newly diagnosed generalized anxiety disorder (GAD) increased from 5. 4% in 2020 to 6. 6% in 2023 The 3-year total prevalence of GAD reached 10. 3%, representing more than 1 in 10 U. S. adults The authors also note that real-world prevalence estimates derived from healthcare claims may…...
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy" (xanomeline and trospium chloride)
2+ week, 1+ day ago (367+ words) High treatment completion and no discontinuations due to lack of efficacy observed across faster and slower switch strategies INDICATION COBENFY" (xanomeline and trospium chloride) is indicated for the treatment of schizophrenia in adults. COBENFY is contraindicated in patients with: Risk…...
Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
3+ week, 4+ day ago (60+ words) Workshop Wednesday, March 25, 2026 3: 30-5: 30 PM CET " Room: Auditorium Posters Thursday, March 26, 2026 12: 00-2: 00 PM CET - Room: Cavaniglia Friday, March 27, 2026 12: 00-2: 00 PM CET - Room: Cavaniglia Saturday, March 28, 2026 12: 00-2: 00 PM CET - Room: Cavaniglia Newron Stefan Weber " CEO; +39 02 6103 46 26, pr@newron. com...
Psychedelics Are Placeholders for More Traditional Depression Therapies: Analysts
1+ mon, 1+ week ago (621+ words) Psychedelic drugs could be heading to the FDA this year, pushed along by a wave of investor and patient enthusiasm. But analysts at William Blair say these treatments are unlikely to seize the entire treatment-resistant depression (TRD) market, leaving plenty…...
Feinstein Institutes" Scientists Discover Brain Circuit That Links Inflammation and Stress Response
1+ mon, 2+ week ago (675+ words) Bio Space Feinstein Institutes" Scientists Discover Brain Circuit That Links Inflammation and Stress Response New study reveals how the brain can "remember" inflammation, replay immune and stress responses, pointing to new possibilities for bioelectronic medicine MANHASSET, N. Y. --(BUSINESS WIRE)--What if…...
Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia
1+ mon, 2+ week ago (48+ words) Bio Space Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia First Patients of 2026 Treated Outside of Sponsor-Led Clinical Trials Under Australia's Regulated Framework...
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
2+ mon, 1+ week ago (134+ words) " The review provides strong scientific rationale to support Alto's drug development approach leveraging its Precision Psychiatry Platform " The authors further highlight a critical industry gap: the historical absence of translatable biomarkers that directly index plasticity changes in humans. Addressing this…...
Neurocrine's Depression Drug Delivers "Surprise' Phase II Miss
5+ mon, 3+ day ago (385+ words) Neurocrine Biosciences" investigational pill NBI-1070770or just "770was unable to significantly improve depression severity in a mid-stage study, slowing the momentum the biotech has built in recent weeks. In a brief announcement on Monday, Neurocrine announced that "770 "did not meet the primary…...
Can Psychedelics Break Through in Depression? Recent Readouts Leave Investors Wanting More
9+ mon, 1+ day ago (880+ words) Over the past three weeks, psychedelics companies and investors have gotten their first look at two key readouts that could influence momentum in the space. Though the notably different market impacts of these announcements came as a surprise to some,…...